Table of Contents
In today’s rapidly evolving healthcare landscape, the demand for fast, accurate, and accessible diagnostic tools has never been greater. Molecular diagnostics, particularly PCR-based testing, has become the gold standard for detecting infectious diseases. At the forefront of this transformation is Bioeksen—a company redefining how diagnostic testing is developed, delivered, and utilized across the globe.
Founded in 2014 by university scientists, Bioeksen emerged from a strong academic foundation with a mission to advance molecular diagnostics. Unlike many biotech companies driven by private investment, Bioeksen has grown through public research funding. This approach has enabled the company to focus on innovation and accessibility rather than short-term commercial gains.
The company gained global recognition during the COVID-19 pandemic, distributing over 200 million PCR tests across 72 countries. Their SARS-CoV-2 testing kits received both FDA Emergency Use Authorization and WHO Emergency Use Listing—milestones that highlight their credibility and global trust.
One of Bioeksen’s most significant contributions is simplifying the PCR testing workflow. Traditionally, PCR testing involves multiple steps, including nucleic acid extraction, reagent preparation, and result interpretation. Bioeksen has streamlined this process through several key innovations:
With these advancements, laboratories can complete testing workflows in as little as 60 minutes.
Bioeksen’s multiplex qPCR panels allow simultaneous detection of multiple pathogens in a single test—up to 30 targets at once. This capability is especially valuable in diagnosing diseases with overlapping symptoms, such as respiratory or gastrointestinal infections.
Their portfolio includes panels for:
This broad coverage ensures that healthcare providers can make faster, more informed decisions.
Bioeksen offers both liquid and lyophilized (freeze-dried) formats:
These options allow laboratories of all sizes and capacities to adopt Bioeksen’s solutions and efficiency.
Efficiency is not just about speed—it’s also about cost-effectiveness. Bioeksen systems are designed to process between 10 and 94 samples in a single run, maximizing throughput without increasing waste.
Their solutions are reported to be up to three times more cost-effective than many point-of-care PCR systems, making advanced diagnostics more accessible, especially in resource-limited settings.
Bioeksen’s mission extends beyond technology. Their vision is to make molecular diagnostics accessible to everyone, everywhere. This commitment is reflected in their global reach and their role as a WHO contractor for pathogen surveillance.
By combining innovation, affordability, and scalability, Bioeksen is helping bridge the gap between advanced diagnostics and real-world healthcare needs.
As infectious diseases continue to evolve, so must the tools used to detect them. Bioeksen’s integrated approach—combining advanced PCR technology, automation, and user-friendly design—represents a significant step forward. In a world where early detection can save lives, solutions like these are not just innovations—they are necessities.
Introduction Classification: Belongs to the family Enterobacteriaceae. Habitat: Widely found in soil, water, plants, and…
Introduction Streptococcus mitis is a Gram-positive, alpha-hemolytic bacterium commonly found as a harmless commensal in…
Introduction An anemometer measures wind speed. It also measures wind pressure. The name comes from…
Introduction TB-LAMP (Tuberculosis Loop-Mediated Isothermal Amplification) is a manual, rapid molecular diagnostic test endorsed by…
Introduction The NALC-NaOH (N-acetyl-L-cysteine–sodium hydroxide) method is the gold standard for processing clinical specimens in…
Introduction The BD BACTEC™ MGIT™ 960 (Mycobacteria Growth Indicator Tube) is a fully automated, high-volume…